Changing the Status Quo of Traditional Drug Development
Our technology allows deeper insight into the effects and potential treatments of metabolic diseases to mitigate impact on human health and streamline the translation from R&D to clinical trials.
our technology
ObaCell®: Empowering research with adipose tissue models that incorporate human diversity and mimic human biology.
our vision
We envision a world where enriched preclinical insights create future therapies that are accessible, equitable, and effective for patients worldwide regardless of demographic and socioeconomic backgrounds.
Our Partners
Our strategic partnerships with distinguished industry leaders not only enhance our company's capabilities but also foster innovation, synergy, and collective success through collaborative efforts.
Our investors
The unwavering support of our investors not only ensures stability but also propels our company towards greater innovation, enabling us to bring our vision closer to reality with every milestone achieved.
Publications
International Journal of Molecular sciences
Adipose Tissue in Breast Cancer Microphysiological Models to Capture Human Diversity in Preclinical Models
STem cells international
Human Adipose Derived Cells in Two- and Three-Dimensional Cultures: Functional Validation of an In Vitro Fat Construct
advanced biology
Biomechanical and Biological Characterization of XGel, a Human-Derived Hydrogel for Stem Cell Expansion and Tissue Engineering
Posters
MPS World SUmmit 2024
ObaCell® Obesity-on-a-Chip, a Platform for Disease Modeling and Drug Development- AI Image Analysis and a GLP-1 Agonist Study
MPS World Summit 2024
Human-derived Biomaterials to Fully Support Microphysiological Systems
AACR 2023
A Patient Derived Xenograft Model for Lung Adenocarcinoma Using ObaGel®, a Human Derived Hydrogel
